key: cord-0037237-rbcge4a1
authors: Har, Bryan Jonathan
title: Cardiology
date: 2015-04-13
journal: Approach to Internal Medicine
DOI: 10.1007/978-3-319-11821-5_2
sha: 91cdea2bada2bdaf4ea0edcb0fe1c656bfcb9ee4
doc_id: 37237
cord_uid: rbcge4a1

myocardial—myocardial infarction, angina, myocarditis

· IV B = unstable angina on oral treatment, symptoms improved but angina with minimal provocation · IV C = unstable angina persists, not manageable on oral treatment or hemodynamically unstable KILLIP CLASS CLASSIFICATION · I = no evidence of heart failure · II = mild to moderate heart failure (S3, lung rales less than half way up, or jugular venous distension) · III = overt pulmonary edema · IV = cardiogenic shock May be considered for patients post-STEMI or NSTEMI with one of the following criteria: (1) atrial fibrillation, (2) left ventricular thrombus, (3) significant left ventricular dysfunction with extensive regional wall motion abnormalities. Start warfarin 5 mg daily within 72 h and continue heparin/LMWH until INR is between 2 and 3 (unless planning angioplasty). Beware bleeding risk. If possible, minimize duration of "triple therapy" (i.e., ASA, P2Y 12 inhibitor, and warfarin), consider GI protection with proton-pump inhibitor, and target lower INR (e.g., 2.0-2. 5 prognostic. Hypotension should be treated with fluid bolus to ensure good preload POSTERIOR INFARCTION -ST depression in V1-V2 in a regular ECG should automatically trigger one to request for posterior (V7-V9) leads to check for posterior MI. Posterior infarct may be associated with inferior infarcts (90%) and lateral infarcts (10%) as the PDA may be supplied by the right or left circumflex coronary artery POSTMI RISK STRATIFICATION · EXTENT OF INFARCT / RESIDUAL FUNCTION -assessment is based on clinical factors (↑ HR, ↓ BP, Killip class, diabetes, renal failure, ↑ WBC, GRACE risk score, TIMI risk score), ECG, biomarkers (CK, troponin), imaging (echocardiogram, MIBI, cardiac MRI), and angiography. Early measurement of LV function, although of prognostic importance, is misleading as myocardium function may improve in first 2 weeks. Medical management according to risk · EXTENT OF MYOCARDIUM AT RISK -assessment is based on exercise stress test, stress echocardiogram, stress sestamibi (ischemic tissue), thallium scan (viable tissue), PET scan, cardiac MRI, angiography. Angioplasty or CABG should be considered · RISK OF ARRHYTHMIA -high risk of VF/VT within the first 48 h, therefore monitor with telemetry.

If it occurs after 48 h, consider antiarrhythmics and early ICD BALLOON PUMP -a long balloon in the descending aorta that deflates during systole and inflates during diastole to augment coronary perfusion and cardiac output as well as decrease afterload. Reasonable for severe refractory ischemia and hemodynamic instability. May be used in conjunction with inotropes. Contraindicated in aortic regurgitation, AAA, aortic dissection, uncontrolled sepsis bleeding disorder, and severe PVD FIBRINOLYTICS USE · INDICATIONS ->120 min anticipated delay from first medical contact to primary PCI, ≥30 , VF) , stroke, dissection, myocardial infarction, death · BARE METAL STENTS VS . DRUG -ELUTING STENTS -instent restenosis is due to fibrosis of coronary vasculature and usually happens 3 months postprocedure. Drug-eluting stents (sirolimus, paclitaxel, everolimus, or zotarolimus) are designed to inhibit cell proliferation and decrease the risk of in-stent restenosis. There has been some controversy regarding higher adverse events in patients with first generation drug-eluting stents (sirolimus or paclitaxel). The most recent outcomes research analysis suggests that newer-generation drug-eluting stents (everolimus or zotarolimus) are associated with a decreased rate of repeat revascularization, stent thrombosis, and no significant difference in mortality · BENEFITS -primary PCI is generally preferred given the superior outcomes compared to fibrinolysis, particularly if (1) For patients with an estimated GFR of 15-60 mL/min/1.73 m 2 , a threshold of 201 pg/mL can be used APPROAC H -"the features evaluated in more than one study with the highest LRs (>3.5) for diagnosing heart failure were the following: the overall clinical judgment, history of heart failure, S3, jugular venous distension, pulmonary venous congestion or interstitial edema on CXR, and atrial fibrillation on ECG. The features evaluated in more than one study with the lowest LRs (<0.60) for diagnosing of heart failure were the following: the overall clinical judgment, no prior history of heart failure, no dyspnea on exertion, the absence of rales, and the absence of radiographic pulmonary venous congestion, or cardiomegaly. The single finding that decreased the likelihood of heart failure the most was a BNP <100 pg/mL. While the findings of this study are useful when assessing dyspneic patients suspected of having heart failure, no individual feature is sufficiently powerful in isolation to rule heart failure in or out. Therefore, an overall clinical impression based on all available information is best. If the appropriate constellation of findings with high LRs for heart failure are present, that may be sufficient to warrant empirical treatment without further urgent investigations" 

★DDDD★ DIETlow salt (<100 mmol/day, 1.5-2 g/day), fluid restriction (1.5-2 L/day) DIURETICSfurosemide 20-120 IV/PO daily-BID with daily adjustments (try to use smallest dose possible to allow ACE inhibitor) ± metolazone 2.5-5 mg PO 30 min before furosemide, spironolactone 12.5-50 mg PO daily or eplerenone 25-50 mg PO daily VASODILATORS -ACE inhibitor ( captopril 6.25-50 mg PO TID, enalapril 1.25-10 mg PO BID, ramipril 2.5-10 mg PO BID, lisinopril 2.5-20 mg PO daily, perindopril 2-8 mg PO daily). ARB ( valsartan 40-160 mg PO BID, candesartan 8-32 mg PO daily). Hydralazine 10-50 mg PO QID and nitrates ( nitropatch 0.4 mg topical daily or isosorbide mononitrate 30-90 mg PO daily). βblockers ( metoprolol tartrate 50-100 mg PO BID, carvedilol 3.125-25 mg PO BID, bisoprolol 2.5-10 mg PO daily) DI G ITALISdigoxin 0.0625-0.25 mg PO daily TREAT UNDERLYIN G CAUSE -CAD (PCI/CABG), aortic stenosis (AV replacement), sleep apnea (CPAP) DEVICES -if ejection fraction <30-35%, consider cardiac resynchronization therapy (CRT/ biventricular pacing) ± implantable cardioverter defibrillators (ICD). Ventricular assist devices may also be considered in selected cases of refractory HF

ACE IN H IBITOR (Garg, JAMA 1995)-hazard ratios for total mortality 0.77 and mortal-ity/hospitalization 0.65 for any patients with LVEF <40%. Target dose = maximum tolerated. Contraindications include SBP <80 mmHg, bilateral renal artery stenosis, severe renal failure, and hyperkalemia ARB (CHARM)-consider substitution with ARB if ACE inhibitor not tolerated (e.g., cough). May also be used as adjunct to ACE inhibitor if β-blocker not tolerated. Contraindications similar to ACE inhibitor H YDRALAZINE/NITRATES (VHEFT I and II, A-HeFT)-less effective than ACE inhibitor. Particularly useful for pregnant patients, African Americans, or those who developed renal insufficiency while on ACE inhibitor, or as add-on therapy ANGIOTENSIN RECEPTORNEPRILYSIN INHIBITOR (McMurray, NEJM 2014, PARADIGM-HF)-combination sacubitril-valsartan demonstrated 16% reduction in all-cause mortality, 20% reduction in death from cardiovascular causes, and 21% reduction heart failure hospitalizations compared to enalapril βBLOCKERS (Foody JAMA 2002)-hazard ratios for total mortality 0.65 and mortality/hospitalization 0.64. May worsen symptoms in first few weeks and may take up to 1 year to see full effect in LVEF. Useful for patients with NYHA II-III (and stable IV) and LVEF <40%, also NYHA I, LVEF <40%, and post-MI. Contraindications include fluid overload and severe asthma. Start only when patient euvolemic SPIRONOLACTONE (RALES 1999, EPHESUS 2003, EMPHASIS-HF 2011)-hazard ratios for all-cause mortality 0.7 and hospitalization for HF, 0.65 for patients with NYHA III-IV, LVEF <35%, and already on maximum medical therapy. Hazard ratios for cardiovascular death/HF hospitalization 0.63 and cardiovascular mortality 0.76 for patients with NYHA II and LVEF ≤30% (or LVEF 31-35% plus QRS duration >130 msec), and already on maximum medical therapy. Caution in elderly and renal failure patients as higher risk of hyperkalemia DI G OXIN (DIG 1997)-hazard ratios for total mortality 0.99 and mortality/hospitalization 0.92. Particularly useful for patients with both HF and atrial fibrillation, or symptomatic HF despite maximum medical therapy 

cardiac (ischemic heart disease, acute aortic regurgitation, acute mitral regurgitation, mitral stenosis/obstruction, arrhythmia), pulmonary (pulmonary embolism, pneumonia), renal (bilateral renal artery stenosis), systemic (hypertension crisis, fever, sepsis, anemia, thyrotoxicosis) 

· OLD AGE , RENAL FAILURE · CARDIAC -ischemia, myocarditis, cardiomyopathy, amyloidosis, cor pulmonale · METABOLIC -hypokalemia, hypomagnesemia, hypernatremia, hypercalcemia, hypoxemia, acid-base imbalance

PATHOPHYSIOLOGY DI G OXIN LEVEL -measurement of serum levels is not routinely necessary as dosing can usually be titrated according to clinical and hemodynamic effects. When measured, serum level should be collected at 12-24 h after the last dose (postdistribution phase). While the upper normal limit is 2.6 nmol/L [2.0 ng/mL], higher digoxin levels may be seen in asymptomatic patients. Low-dose digoxin, resulting in serum levels 0.5-0.9 nmol/L [0.4-0.7 ng/mL] is associated with possible survival benefit compared to ≥1 nmol/L [≥0.78 ng/ mL] in HF patients MECHANISM -digitalis acts by inhibiting the membrane-bound Na/K ATPase transport system. This leads to intracellular loss of K and gain of Na. Increase in intracellular Ca leads to ↑ cardiac contractility. Digoxin also exerts a vagotonic action, which slows conduction through the SA and AV node and helps to control heart rate PRECIPITANTS OF DI G OXIN TOXICITY -toxicity is not merely related to serum levels, but also digoxin dosing (e.g., acute overdose), other medications (e.g., non-potassium sparing diuretics), and conditions (e.g., renal insufficiency, acute coronary syndromes, cardiac amyloidosis, hypothyroidism). For instance, hypokalemia, hypernatremia, hypomagnesemia and acidosis predispose to toxicity even at low-serum digoxin levels because of their depressive effects on the Na/K ATPase pump. In contrast, hyperkalemia occurs in acute toxicity and is directly related to prognosis

· NEUROLOGICAL -delirium, hallucination, blurred vision with altered color perception, headaches, dizziness · CARDIAC -bradycardia, high-degree AV block, paroxysmal atrial tachycardia (often 2:1 AV conduction), unifocal or multifocal PVCs, bidirectional ventricular tachycardia, accelerated junctional tachycardia · G I -anorexia, N&V, diarrhea, abdominal pain · METABOLIC -hyperkalemia 

Cardiac Examination

A WAVE -atrial contraction · PROMINENT A WAVE -tricuspid stenosis, pulmonary stenosis, pulmonary hypertension, hypertrophic cardiomyopathy, and Ebstein's anomaly · CANNON A WAVE -AV dissociation (complete heart block, ventricular tachycardia) (right atrium contracts against closed tricuspid valve) · DECREASED A WAVE -dilated right atrium · ABSENT A WAVE -atrial fibrillation X DESCENT -atrial relaxation. S1 starts · DECREASED X DESCENT -atrial fibrillation · X DESCENT DEEPER THAN Y DESCENT -tamponade C WAVE -bulging of tricuspid valve into right atrium during ventricular isometric contraction X' DESCENT -descent of the base of the heart during systole V WAVE -atrial filling. S2 just before peak of v · DOMINANT V WAVE -tricuspid regurgitation (cv wave), right heart failure, atrial septal defect Y DESCENT -opening of tricuspid valve/atrial emptying · RAPID STEEP Y DESCENT -constrictive pericarditis (square root sign), severe right heart failure · DECREASED Y DESCENT -tricuspid stenosis · SUSTAINED APICAL BEAT (outward impulse extends to, or past, S2)-left ventricular pressure overload (aortic stenosis), volume overload (aortic regurgitation, VSD), severe cardiomyopathy, or ventricular aneurysm · RETRACTING APICAL BEAT (retraction during systole; inward motion begins at S1, outward impuse after S2)-constrictive pericarditis (up to 90%), tricuspid regurgitation · SUSTAINED LEFT PARASTERNAL MOVEMENT ("lift/ heave")-tricuspid regurgitation, mitral regurgitation · PALPABLE P2 -pulmonary hypertension in mitral stenosis, LR+ 3.6

TEC H NIQUE -S1, S2, and physiological splitting of S2 are best heard over the base. Identification of S3 and S4 requires conscious effort listening for low pitched sounds over the apex (using the bell) DISTIN G UIS H IN G S1 FROM S2 -time with carotid pulse, diastole longer than systole, S2 louder than S1 at the base, S1 is low pitched and longer while S2 is high pitched and shorter, S2 often split INTENSITY OF S1 AND S2 · LOUD P2 > A2 AT PULMONIC AREA -increased pulmonary pressure (left ventricular failure, mitral stenosis, pulmonary hypertension), increased pulmonary flow (atrial septal defect) · LOUD S2 AT AORTIC AREA -hypertension, hyperdynamic states (fever, hyperthyroidism, anemia) · SOFT S2 OVER AORTIC AREA -severe aortic stenosis · LOUD S1 AT MITRAL AREA -mitral stenosis · SOFT S1 -mitral regurgitation, left bundle branch block, short PR interval SPLITTIN G OF S2 · FIXED SPLITTING (splitting same degree during both inspiration and expiration)-atrial septal defect, right ventricular failure · WIDE SPLITTING (splitting greater during inspiration than expiration)-right bundle branch block, pulmonary stenosis, pulmonary hypertension · PARADOXICAL ( REVERSED ) SPLITTING (splitting only during expiration)-left bundle branch block, severe aortic stenosis, RV pacing 1. S4 is usually best heart at apex with the bell while S1 is best heard at base 2. S4 is usually more widely separated from S1 than splitting of S1 3. S4 is loudest at the start of expiration, softest at mid-inspiration 4. S4 may be accentuated by lying down, exercise, or forced inspiration with closed glottis 5. S4 has a lower pitch than S1 DISTIN G UIS H IN G FEATURES BETWEEN S3 AND OPENIN G SNAP 1. S3 has a lower pitch than opening snap 2. S3 occurs later than opening snap DISTIN G UIS H IN G FEATURES BETWEEN S3 AND S4 1. S3 has a lower pitch than S4 2. S3 is closer to S2 while S4 is closer to S1 3. Left ventricular S3 is louder at the apex while right ventricular S3 or S4 is usually best heart at left sternal border or at the base MURMURS TIMIN G · MID -SYSTOLIC -aortic stenosis, aortic sclerosis, pulmonary stenosis, hypertrophic obstructive cardiomyopathy, atrial septal defect, flow murmurs (fever, pregnancy, hyperthyroidism, anemia, aortic regurgitation due to high flow) · PANSYSTOLIC -mitral regurgitation, tricuspid regurgitation, ventricular septal defect, aortopulmonary shunts · LATE SYSTOLIC -mitral valve prolapse, papillary muscle dysfunction · EARLY DIASTOLIC -aortic regurgitation, pulmonary regurgitation · MID -DIASTOLIC -mitral stenosis, tricuspid stenosis, atrial myxoma, Austin Flint murmur of aortic regurgitation, Carey Coombs murmur during acute phase of rheumatic fever · PRE -SYSTOLIC -mitral stenosis, tricuspid stenosis, atrial myxoma · CONTINUOUS MURMURS -patent ductus arteriosus, arteriovenous fistula, aortopulmonary connection, venous hum, mammary souffle INTENSITY -grade I (barely audible), grade II (faint but can be heard immediately), grade III (easily heard), grade IV (loud AND associated with palpable thrill), grade V (very loud, can be heard with the stethoscope half off chest), grade VI (very loud, can be heard with stethoscope off chest wall) QUALITY -depends on the pitch, may be musical, harsh, blowing, rumbling, scratchy, grunting, or squeaky CONFI G URATION -crescendo, decrescendo, crescendo-decrescendo, plateau, holosystolic LOCATION -aortic valve (RUSB), pulmonary valve (LUSB), tricuspid valve (LLSB), mitral valve (apex) RADIATION -aortic valve (carotids), pulmonary valve (left shoulder), tricuspid valve (xyphoid, right of sternum), mitral valve (axilla) MANEUVERS · RESPIRATION -rightsided murmurs typically increase with inspiration (except pulmonic click) or sustained abdominal pressure (↑ venous return), while leftsided murmurs are generally louder during expiration · V ALSALVA MANEUVER (↓ venous return and ↑ systemic arterial resistance)-most murmurs decrease in length and intensity during the Valsalva maneuver. Two exceptions are the systolic murmur of hypertrophic cardiomyopathy , which usually becomes much louder, and the systolic murmur of mitral valve prolapse , which becomes longer and often louder (click moves closer to S1) · POSITIONAL CHANGES -most murmurs diminish with standing due to reduced preload. However, the murmur of hypertrophic cardiomyopathy becomes louder and the murmur of mitral valve prolapse lengthens and often is intensified. Squatting (or usually passive leg raising, both ↑ venous return and ↑ systemic arterial resistance) produces opposite effect Loud heart sounds are usually due to mild-moderate stenotic lesions, while light heart sounds are usually due to regurgitant or severe stenotic lesions c Regurgitant murmurs usually start early, while stenotic murmurs tend to start mid-way d For mitral valve prolapse, maneuvers that increase murmur intensity also move both the click and murmur closer to S1 e For mitral stenosis, the murmur is classically described as mid-diastolic with presystolic accentuation f All the following special signs for aortic regurgitation are related to increased pulse pressure. These include Quincke's sign (pulsatile refill in capillary bed of finger nails), Becker's sign (pulsatile retinal artery), deMusset's sign (head bob), Mueller's sign (pulsatile uvula), Mayne's sign (DBP ↓ 15 mmHg with arm raised), Gerhardt's sign (pulsatile spleen), Rosenbach's sign (pulsatile liver), Traube's sign (pistol shot sound over femoral arteries), Duroziez's sign (femoral artery bruit with compression), Hill's sign (popliteal SBP > brachial SBP by 60 mmHg)

INNOCENT MURMURS -in otherwise healthy younger patients. Systolic murmurs tend to be mid-systolic, grade 1 or 2 (possibly 3), loudest over LUSB, and do not radiate. Murmurs that are associated with systolic thrill (LR+ 12), holosystolic (LR+ 8.7), loud (LR+ 6.5), or plateau-shaped (LR+ 4.1) are more likely to be significant. Diastolic murmurs are always abnormal

AORTIC STENOSIS -"presence of any of following significantly increases the likelihood of aortic stenosis: effort syncope, slow carotid upstroke, late or mid peaking systolic murmur, decreased or absent S2, apical-carotid delay, brachioradial delay." "The presence of AS requires detection of a systolic murmur, generally radiating to the right clavicle. " 

-"for cardiologists, absence of a mitral area murmur or a late systolic/holosystolic murmur significantly reduces the likelihood of mitral regurgitation, except in the setting of acute MI. Cardiologists can accurately distinguish left-sided regurgitant murmurs, such as mitral regurgitation and ventricular septal defect, using transient arterial occlusion" TRICUSPID RE G UR G ITATION -"cardiologists can accurately detect the murmur of tricuspid regurgitation. Cardiologists can accurately rule in and rule out tricuspid regurgitation using the quiet inspiration and sustained abdominal pressure maneuvers" H YPERTROP H IC CARDIOMYOPAT H Y -"cardiologists can rule in or rule out hypertrophic cardiomyopathy by evaluating for decreased murmur intensity with passive leg elevation or increased murmur intensity when the patient goes from a squatting to standing position " MITRAL VALVE PROLAPSE -"a systolic click , with or without systolic murmur , is sufficient for the diagnosis of mitral valve prolapse. The

absence of both a systolic click and murmur significantly reduces the likelihood of echocardiographic mitral valve prolapse. In patients with echocardiographic mitral valve prolapse, a holosystolic murmur without a systolic click significantly increases the likelihood of long term complications, whereas absence of both a systolic click and murmur significantly reduces the likelihood of long term complications" JAMA 1997 277:7

-"when a cardiologist hears the typical murmur of aortic regurgitation, the likelihood of mild or greater aortic regurgitation is increased significantly. The absence of a typical diastolic murmur significantly reduces the likelihood of aortic regurgitation" MITRAL STENOSIS -"presence of a middiastolic murmur significantly increases the likelihood of mitral stenosis, while absence of a mid-diastolic murmur significantly reduces the likelihood of mitral stenosis" PULMONARY RE G UR G ITATION -"when a cardiologist hears a typical pulmonary regurgitation murmur, the likelihood of pulmonary regurgitation increases significantly. Absence of a typical murmur does not alter the likelihood of pulmonary regurgitation" JAMA 1999 281:23 

AORTIC VALVE AREA AND SEVERITY · NORMAL = peak velocity <2 m/s, area = 3-4 cm 2 · MILD = peak velocity 2.0-2.9 m/s, mean gradient <20 mmHg, area = 1.5-2 cm 2 · MODERATE = peak velocity 3.0-3.9 m/s, mean gradient 20-39 mmHg, area = 1-1.5 cm 2 · SEVERE = peak velocity ≥4 m/s, mean gradient >40 mmHg, area = ≤1 cm 2 (or indexed area ≤ 0.6 cm 2 /m 2 ) · SYMPTOMS -usually do not appear until valve ≤1 cm 2 . The significance of valve area depends on patient size (larger patient = more severe for same valve area) · PROGRESSION -valve area decreases by ~0. 

PATHOPHYSIOLOGY -leaky aortic valve → initial compensation with left ventricular dilatation and eccentric hypertrophy (palpitations, atypical chest pain), wide pulse pressure (due to increased stroke volume with elevation in SBP and regurgitation with rapid collapse of the arteries and a low diastolic blood pressure) → eventually decompensation leading to left ventricular dysfunction (heart failure)

P H YSICAL · GENERAL APPEARANCE -Marfan's syndrome, ankylosing spondylitis, Argyll Robertson pupils, Quincke ' s sign (pulsatile refill in capillary bed of finger nails), digital throb, Becker ' s sign (visible pulsations of the retinal arteries and pupils), deMusset ' s sign (head bob occurring with each heart beat), Mueller ' s sign (systolic pulsations of the uvula) · VITALS -wide pulse pressure, water hammer (tapping impulse in forearm, especially when arm is raised vertically), Corrigan ' s pulse , Mayne ' s sign (>15 mmHg decrease in diastolic blood pressure with arm elevation) · CARDIAC -soft S1, left-sided S3 (heart failure), diastolic murmur (early diastolic or holodiastolic, blowing, over left upper sternal border), Austin Flint murmur (mid/late diastolic rumble, over apex) and midsystolic flow murmur · OTHERS -G erhardt ' s sign (systolic pulsations of the spleen), Rosenbach ' s sign (systolic pulsations of the liver), Traube ' s sign (pistol shot pulse with systolic and diastolic sounds heard over the femoral arteries), Duroziez ' s sign (systolic and diastolic bruit heard when the femoral artery is partially compressed), H ill ' s sign (popliteal cuff systolic pressure exceeding brachial pressure by >60 mmHg). Note that all the special signs are due to increased pulse pressure 

H ISTORY -symptoms related to pulmonary hypertension (dyspnea, hemoptysis, chest pain), symptoms related to right heart failure (hepatomegaly, ascites, edema), hoarseness (Ortner's syndrome, due to enlarged left atrium compressing on recurrent laryngeal nerve), complications (endocarditis, thromboembolism), past medical history (rheumatic fever), medications P H YSICAL · GENERAL APPEARANCE -tachypnea, peripheral cyanosis, mitral facies (purple patches on cheeks secondary to vasoconstriction) · VITALS -decreased pulse volume · JVP -prominent a wave (pulmonary hypertension), absent a wave (atrial fibrillation), cv wave (tricuspid regurgitation) · CARDIAC -right ventricular heave, palpable P2 (pulmonary hypertension), loud S1 (valve cusps widely apart at the onset of systole) in early disease, soft S1 in severe disease (valves rigid), loud S2, absent S3, opening snap (over apex and left lower sternal border; the earlier the opening snap, the more severe the stenosis), low pitch diastolic rumble (over

apex, left decubitus position in expiration) ± pre-systolic accentuation, tricuspid regurgitation · ABDOMINAL -hepatomegaly, ascites, edema

· PROGRESSIVE -mitral valve area (MVA) >1.5 cm 2 , diastolic pressure half-time <150 ms · SEVERE -MVA ≤1.5 cm 2 (MVA ≤1.0 cm 2 with very severe MS), diastolic pressure half-time ≥150 ms (diastolic pressure half-time ≥220 ms with very severe MS); associated with severe left atrial enlargement and pulmonary artery systolic pressure >30 mmHg. Note, transmitral mean gradient often >5-10 mmHg but mean pressure gradient varies greatly according to heart rate · SYMPTOMS -often present when MVA ≤1.5 cm 2 (i.e., with severe MS). Onset of symptoms may be precipitated by exercise, emotional stress, infection, pregnancy, or rapid atrial fibrillation PRO G RESSION -approximately 0.1-0.3 cm 2 / year. Initially slow stable course (latent period) of 20-40 years between rheumatic fever and symptoms. From onset of symptoms (accelerated period), around 10 years until disability. Overall 10-year survival is 50-60% in untreated symptomatic MS, >80% in asymptomatic. Median survival <3 years with severe pulmonary hypertension

MEDICATIONSnegative chronotropic agents and HR control to prolong diastolic filling (β-blockers, non-dihydropyridine calcium channel blockers). Anticoagulation for patients with concomitant atrial fibrillation (irrespective of CHADS 2 score), left atrial thrombus, or prior embolic event (even if in sinus rhythm). Prophylaxis for rheumatic fever (secondary prevention) FOLLOWUP -any change in symptoms warrant reevaluation and echocardiogram. Otherwise, yearly evaluation in asymptomatic patients including CXR and ECG. Yearly echocardiogram for severe MS PROCEDURES -indicated when symptomatic severe mitral stenosis. Percutaneous balloon mitral valvuloplasty (particularly for patients with non-calcified mitral valve, no left atrial thrombus, mild mitral regurgitation, and no other cardiac interventions) is equivalent to surgical valvuloplasty in terms of success. Average increase in valve area is 1.0 cm 2 

CLINICAL FEATURES -exertional dyspnea, fatigue, decreased S1, widely split S2, S3, holosystolic murmur (over apex), displaced and enlarged apex MANAGEMENT MEDICATIONS -no specific therapy for MR. Treat concomitant atrial fibrillation if present FOLLOWUP -asymptomatic mild MR with normal LV function and no LV dilatation can be followed annually. Asymptomatic severe MR should be seen every 6-12 months with echocardiogram at the time of assessment PROCEDURESmitral valve repair (generally better outcome if technically possible) or replacement if symptomatic, atrial fibrillation, pulmonary hypertension, end-systolic dimension ≥40 mm, or LVEF 30-60%. Transcatheter mitral valve repair may be considered for severely symptomatic, severe primary MR with prohibitive surgical risk

· PATHOPHYSIOLOGY -leaky tricuspid valve → right atrium and ventricle volume overload → eventually decompensation leading to right heart failure (hepatosplenomegaly, ascites, peripheral edema) · CAUSES -right ventricular dilatation (left heart failure, pulmonary hypertension, Eisenmenger syndrome, pulmonic stenosis), valve abnormality (rheumatic heart disease, infective endocarditis, Ebstein's anomaly). Rarely is it due to isolated tricuspid valve abnormality · CLINICAL FEATURES -cachexia, jaundice (congestive hepatomegaly), JVP cv wave, RV heave, S3 (with dilated RV), S4 (with stiff RV), holosystolic murmur (over left lower sternal border), edema · INVESTIGATIONS -ECG (P pulmonale, RVH), CXR (cardiomegaly), echocardiogram, cardiac catheterization, rule out intracardiac shunts · TREATMENTS -valve repair or replacement if severe symptoms MITRAL VALVE PROLAPSE · PATHOPHYSIOLOGY -prevalence 0.6-2.5% of population. May be sporadic or familial connective tissue disorder with morphologic abnormalities of the mitral valve (increased leaflet thickness and redundancy, chordal elongation, and sagging of the leaflets into the left atrium in systole) · TREATMENTS -ASA 75-325 mg PO · CANCER -about 50% of patients with S. bovis endocarditis also have neoplasms of the GI tract RISK FACTORS FOR ENDOCARDITIS · HIGH RISK -complex cyanotic congenital heart disease (unrepaired or incompletely repaired cyanotic congenital heart disease, including palliative shunts and conduits; completely repaired congenital heart defect with prosthetic material or device, whether placed by surgery or by catheter intervention, during the first 6 months after the procedure; repaired congenital heart disease with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device), surgically constructed systemic pulmonary shunts, previous infective endocarditis, prosthetic heart valve, cardiac transplantation recipients who develop cardiac valvulopathy · MODERATE RISK -most other congenital heart diseases, acquired valvular disease (rheumatic heart disease, mitral/aortic/pulmonary/tricuspid stenosis or regurgitation), mitral valve prolapse with valvular regurgitation or leaflet thickening, hypertrophic cardiomyopathy · LOW OR NO RISK -secundum ASD or surgically repaired ASD, VSD, PDA, mitral valve prolapse with thin leaflets in the absence of regurgitation, ischemic heart disease, previous CABG · NON -CARDIAC -IDU, poor dental hygiene, longterm hemodialysis, long-term indwelling catheter, procedures (GU, GI, surgical wound infection), diabetes, HIV 

Legionella , Brucella , Bartonella , Coxiella burnetii (Q fever), Histoplasma , Tropheryma whippelii MARANTIC ENDOCARDITIS -non-bacterial thrombotic endocarditis secondary to malignancy (usually adenocarcinoma) or SLE (Libman-Sacks endocarditis)

H ISTORY -fever, murmur, dyspnea, chest pain, anorexia, weight loss, malaise, night sweats, complications (painful nodules, rash, stroke, myocardial infarction, any infections), past medical history (structural heart disease, recent procedures [dental, GI, GU], IDU, SLE, malignancy), medications P H YSICAL -fever, splinter hemorrhages, clubbing, Osler nodes (tender, subcutaneous nodules in pulp of digits or thenar eminence), Janeway lesions (nontender, erythematous, hemorrhagic pustular lesions on palms or soles), needle track marks, petechiae over conjunctivae and oral mucosa, Roth spots (pale areas surrounded by hemorrhage on fundoscopic examination), lymphadenopathy, respiratory examination (HF), murmur (regurgitant), splenomegaly, petechiae over legs H I GH INDEX OF SUSPICION -always consider endocarditis in the differential when dealing with fever of unknown origin, persistent bacteremia, HF, MI, myocarditis, pericarditis, stroke, pneumonia, pulmonary embolism, splenic infarction, glomerulonephritis, septic arthritis, and osteomyelitis. All patients with S. aureus bacteremia should undergo echocardiography (25% have IE)

MODIFIED DUKE'S CRITERIA · MAJOR -positive blood culture × 2 (or positive blood culture × 1 for C. burnetii ), echocardiographic evidence (oscillating intracardiac mass, abscess, new partial dehiscence of a prosthetic valve), new murmur · MINOR -fever (>38 °C [100.4 °F]), risk factor (cardiac conditions, IDU), vascular phenomena (major arterial emboli, septic pulmonary infarct, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, Janeway lesions), immunologic phenomena ( glomerulonephritis, Osler nodes, Roth spots, rheumatoid factor), positive blood culture not meeting major criteria · DIAGNOSIS -likely endocarditis if 2 major, 1 major plus 2 minor, or 5 minor criteria EC H OCARDIO G RAM -transesophageal echocardiogram (TEE sens 90-100%, spc 95-100%) preferred over transthoracic echocardiogram (TTE sens 50-80%, spc 90%) for detecting vegetations, perivalvular extension of infection and abscesses, diagnosing prosthetic valve endocarditis, and for differentiating between uncomplicated Staphylococcus aureus bacteremia and endocarditis PRO G NOSIS -mortality of 25-50% for prosthetic valve endocarditis, 35% for Staphylococcal endocarditis and 10% for Streptococcal endocarditis MANAGEMENT EMPIRIC ANTIBIOTIC T H ERAPYnative valve and non -IDU ( ampicillin 2 g IV q4h or cloxacillin 2 g IV q4h plus gentamicin 1 mg/kg IV q8h, or vancomycin 1 g IV q12h plus gentamicin 1 mg/kg IV q8h), native valve and IDU ( cloxacillin 2 g IV q4h plus gentamicin 1 mg/kg IV q8h or vancomycin 1 g IV q12h plus gentamicin 1 mg/kg IV q8h), prosthetic valve ( vancomycin 1 g IV q12h plus gentamicin 1 mg/kg IV q8h plus rifampin 600 mg PO daily) TAR G ETED ANTIBIOTIC T H ERAPY (please refer to the Sanford Guide to Antimicrobial Therapy for up to date recommendations)-Streptococci ( penicillin G 2-3MU IV q4h or ceftriaxone 2 g IV/IM q24h × 4 weeks. Gentamicin 1 mg/kg IV q24h × 2 weeks may be added in certain circumstances to shorten the course by 2 weeks). Penicillinsensitive Enterococci ( ampicillin 2 g IV q4h or vancomycin 1 g IV q12h × 4-6 weeks, plus gentamicin 1 mg/kg IV q8h × 4-6 weeks for native valve). Penicillinresistant Enterococci ( vancomycin 1 g IV q12h × 6 weeks, plus gentamicin 1 mg/kg IV q8h × 6 weeks for native valve). S . aureus ( cloxacillin 2 g IV q6h or nafcillin or oxacillin 3 g IV q6h or cefazolin 2 g IV q8h × 2-6 weeks [depending on right-or left-sided valve] ± gentamicin 1 mg/kg IV q8h × 3-5 days: for native valve). · HIGH -RISK CONDITIONS -prosthetic valve, prosthetic material used for valve repair, unrepaired cyanotic congenital heart defect, repaired cyanotic congenital heart defect with residual defects at the site or adjacent to the site of the prosthetic device, completely repaired cyanotic congenital heart defect with prosthetic material or device during first 6 months after procedure, cardiac transplant recipients with valvulopathy, previous endocarditis · PROCEDURES · ORAL CAVITY -dental procedures that involve manipulation of gingival or peripical region of teeth, perforation of oral mucosa · RESPIRATORY TRACT -tonsillectomy, adenoidectomy, bronchoscopy with a rigid bronchoscope, or flexible bronchoscopy if biopsied · GI / GU TRACT -prophylaxis generally not recommended · PROPHYLAXIS REGIMENS -give one of the following 30-60 min prior to procedure: amoxicillin 2 g PO, ampicillin 2 g IM/IV, cefazolin 1 g IV/IM, ceftriaxone 1 g IV/IM, cephalexin 2 g PO, clindamycin 600 mg PO/IM/IV, azithromycin 500 mg PO, clarithromycin 500 mg PO 

ANATOMY -SA node (RCA 59%, LAD 38%, both 3%) → AV node (RCA 90%, LCX 10%) → bundle of His (RCA) → right bundle (LAD), left anterior fascicle (LAD, RCA), and left posterior fascicle (RCA, LAD) RBBB -QRS ≥120 ms, slurred S wave in I and V6 and rSR' in V1-3 with R' taller than r. May also see QR' complex in V1 (suggestive of old or new infarct). QRS polarity positive in V1-2. Causes include LAD involvement/anterior infarction, may be benign in young people LBBB -QRS ≥120 ms, broad notched or slurred R in I, aVL, V5, and V6, with no Q waves; broad monomorphic S in V1, may have small r wave. QRS polarity negative in V1-2. Causes include hypertension, CAD, dilated cardiomyopathy, rheumatic heart disease, infiltrative diseases, benign or idiopathic LEFT ANTERIOR FASCICULAR BLOCK -QRS <120 ms, left axis deviation −45° to −90°, qR in aVL, R-peak time in aVL of 45 ms or more. May be benign, LAD involvement/anterior infarction. Shortcut to diagnosis-I up, II down, aVF down LEFT POSTERIOR FASCICULAR BLOCK -right axis deviation 90-180°, QRS <120 ms, rS in I and aVL, and qR in III and aVF

NORMAL -QTc = square root (QT in seconds/RR interval in seconds); QT <50% of RR interval; normal QTc 390-460 ms (women), 390-450 ms (men) CAUSESgenetic , metabolic (hypokalemia, hypomagnesemia, hypocalcemia), antiarrhythmics (quinidine, procainamide, amiodarone, sotalol), antibiotics (macrolide, trimethoprim-sulfamethoxazole, fluoroquinolone), psychotropics (TCA, SSRI, haloperidol, risperidone), analgesics (methadone), structural heart disease (HF, LVH, acute ischemia), others (HIV, anorexia nervosa, stroke, brain injury) PRO G RESSION -may result in torsades de pointes, VT, and sudden death (amiodarone less likely) TREATMENTS -remove offending agent(s), overdrive pacing, isoproterenol infusion, magnesium

RAE -tall peaked P in II and aVF (>2.5 mm high); large initial component of biphasic P in V1 (p pulmonale) LAE -wide notched P in II (>2.5 mm long); biphasic P in V1 with broad negative phase; P wave duration >120 ms (p mitrale) LVH -tall R in aVL (>11 mm); R in V5 or V6 (whichever is taller) plus S in V1 >35 mm; R in V5 or R in V6 > 27 mm; poor R wave progression in precordial leads; ST depression and T wave inversion in lateral leads (I, aVL, V5-6) suggestive of ventricular strain; R in aVL plus S in V3 >28 mm in male or >20 mm in female (Cornell criteria 

HYPERCALCEMIA -short QT HYPOCALCEMIA -prolonged QT WOLFFPARKINSONWHITE SYNDROMEshort PR (<120 ms), delta wave, prolonged QRS (>120 ms), symptomatic tachycardia. Pharmacological treatments include amiodarone and procainamide. AV nodal blocking drugs ( adenosine , βblockers , verapamil / diltiazem , digoxin ) are contraindicated in patients with WPW and AF as they may precipitate VF . Consider catheter ablation if symptomatic arrhythmias, AF, or atrial flutter. If failed, consider surgical ablation BRUGADA SYNDROME -type 1: high take-off and cove-shaped ST-segment elevation (≥2 mm) in V1-V2. Type 2: saddle-back ST-T pattern in V1-V2

ID -name and age, date, technique (12 lead, calibration

RHYTHM -regular/irregular, wide/narrow complex, sinus, atrial, atrioventricular, ventricular

AXIS -deviation, rotation

PR INTERVAL -normal 120-200 ms; first, second, third degree AV block

QRS INTERVAL -normal 80-110 ms, intraventricular conduction delay 110-120 ms

QT INTERVAL -QT <50% of RR interval

ISCHEMIA -ST elevation/depression, T wave inversion 10. INFARCTION -Q waves 11. SPECIAL CONDITIONS

H ISTORY -blood pressure levels, ambulatory/ home monitoring, complications and hypertensive end organ damage, other cardiac risk factors (smoking, diabetes, dyslipidemia, obesity), past medical history (thyroid, renal, or adrenal disorders), medications (antihypertensives, steroids, illicit drugs) P H YSICAL -vitals (heart rate, blood pressure), obesity (sleep apnea), moon facies and thoracocervical fat pad (Cushing's), low-pitched voice and acral enlargement (acromegaly), upper body better developed and continuous murmur over precordium/back (coarctation), narrowed oropharynx and ↑ neck circumference (OSA), goiter (hyperthyroidism), aortic regurgitation (aortic dissection), striae, renal bruits (renal artery stenosis), abdominal masses (polycystic kidney disease, adrenal tumors), radiofemoral delay and weak femoral pulses (coarctation). Assess complications including retinopathy, stroke, HF, AAA, and PVD MEASURIN G BLOOD PRESSURE -NEJM 2009 360 : e6

during first visit ? · Yes → hypertension diagnosed · No → proceed to step 2 2. What is the blood pressure during initial visit ? · SBP ≥180 mmHg and/or DBP ≥110 mmHg → repeat BP at least 2 more times at the same visit (discard first reading and average latter 2 readings). If mean BP 180/110 or greater, diagnosis of hypertension is confirmed · SBP 140-179 mmHg and/or DBP 90-109 mmHg (or mean automated office BP taken using an automated device that performs multiple readings with the patient alone in the room is SBP 135-179 and/or DBP 85-109 mmHg), then obtain out-of-office readings before second visit · SBP 130-139 and/or DBP 85-89 mmHg → annual follow-up 3. Out-of-office readings can be measured using 24-hour ambulatory monitoring (ABPM) or a home BP series (HBPM 0.5 APPROAC H -"given the high prevalence (7-31%) of innocent abdominal bruits in the younger age groups, it is recommended that if a systolic abdominal bruit is detected in a young, normotensive, asymptomatic individual, no further investigations are warranted. In view of the low sensitivity, the absence of a systolic bruit is not sufficient to exclude the diagnosis of renovascular hypertension. In view of the high specificity, the presence of a systolic bruit (in particular a systolic-diastolic bruit) in a hypertensive patient is suggestive of renovascular hypertension. In view of the lack of evidence to support characterizing bruits as to pitch, intensity and location, bruits should be reported only as systolic or systolic/diastolic" JAMA 

HYPERTHYROIDISM -tachycardia, non-specific ST-T changes, biphasic T in V2-V6 DIGITALIS EFFECT -slowing SA, AV. Gradual downward sloping/scooping of ST. ST depression in I, II, aVF, V2-V6 DIGITALIS TOXICITY -unifocal or multifocal PVCs, first degree heart block, ventricular bigeminy, paroxysmal atrial tachycardia (often with 2:1 AV conduction), bidirectional VT, atrial fibrillation with complete heart block (regular escape rhythm)HYPERKALEMIA -tall, peaked T wave (especially precordial leads. Definitions of "tall T wave" include a height >5 mm in limb lead or 10 mm in precordial lead or a T wave height >50% of the entire QRS excursion in same lead), widened QRS, wide and flat P wave HYPOKALEMIA -flattened T wave/inversion, U wave COPD -RAD, ↓ amplitude, multifocal atrial tachycardia